Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program Newron Pharmaceuticals S.p.A. a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that…
Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization…
Australian Breast Cancer Innovators Close $27M Private Funding Round OncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™.…
Owlet Announces Strategic DME Partnership with PromptCare to Expand Distribution of Pediatric Pulse Oximeter, BabySat® Owlet, Inc. the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading national respiratory services and durable medical equipment (DME)…
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU)…
Dr. Joseph Chang Launches Update to Bestselling Book “The Aging Myth” With 15 More Years of Breakthrough Research on Cellular Wellness Nu Skin Enterprises Inc. today announced the relaunch of “The Aging Myth: Unlocking the Mysteries of Looking and Feeling…
Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained and Significant Weight Loss in Phase 2b Trial Pfizer Inc. today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor…
Exelixis Announces FDA Acceptance of New Drug Application for Zanzalintinib Combined with Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Exelixis, Inc. today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for…
Lilly Establishes New Injectable Medicine and Device ManufacturingLilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility Eli Lilly and Company today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site…
ICON’s Accellacare Site Network Enhances Oncology Research Through New Cancer Institute Partnership ICON plc today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health…
Bayer to Showcase New Phase III Data and Innovations in Radiology Portfolio at ECR 2026 Bayer will present advancements of its comprehensive radiology portfolio at the 2026 European Congress of Radiology (ECR) taking place from March 4-8, 2026, in Vienna,…
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in Relapsed/Refractory DLBCL AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator’s choice of chemoimmunotherapy in…
